Physicochemical and mechanical properties of carbamazepine cocrystals with saccharin

Pharmaceutical Development and Technology

Volumn 17, Issue 4, 2012, Pages 457-465

  Rahman, Ziyaur ^a   Samy, Raghu ^a   Sayeed, Vilayat A ^b   Khan, Mansoor A ^a  

^a Center of Drug Evaluation and Research   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Carbamazepine; Dehydrate; Intrinsic dissolution; Saccharin; Solubility; Stability

Indexed keywords

CARBAMAZEPINE; SACCHARIN;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; DRUG STABILITY; INFRARED SPECTROSCOPY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; TENSILE STRENGTH; X RAY DIFFRACTION;

ANTICONVULSANTS; CALORIMETRY, DIFFERENTIAL SCANNING; CARBAMAZEPINE; COMPRESSIVE STRENGTH; CRYSTALLIZATION; DRUG STABILITY; POWDER DIFFRACTION; SACCHARIN; SOLUBILITY; X-RAY DIFFRACTION;

EID: 84862286868     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2010.546412     Document Type: Article

References (43)

1. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 020712s030lbl.pdf FDA label carbatrol
2. Moneghini M, Voinovich D, Perissutti B, Princivalle F.Action of carriers on carbamazepine dissolution.Pharm Dev Technol 2002;7:289-296.
3. Douroumis D, Fahr A.Stable carbamazepine colloidal systems using the cosolvent technique.Eur J Pharm Sci.2007;30:367-374.
4. Rustichelli C, Gamberini G, Ferioli V, Gamberini M, Ficarra R, Tommasini S.Solid-state study of polymorphic drugs: Carbamazepine.J Pharm Biomed Anal 2000;23:41-54.
5. Grzesiak AL, Lang M, Kim K, Matzger AJ.Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of the form 1.J Pharm Sci 2003;92:2260-2271.
6. Behme RJ, Brooke D.Heat of fusion measurement of a low melting polymorph of carbamazepine that undergoes multiple-phase changes during differential scanning calorimetry analysis.J Pharm Sci 1991;80:986-990.
7. Hickey MB, Peterson ML, Scoppettuolo LA, Morrisette SL, Vetter A, Guzmán H, Remenar JF, Zhang Z, Tawa MD, Haley S, Zaworotko MJ, Almarsson O.Performance comparison of a cocrystal of carbamazepine with marketed product.Eur J Pharm Biopharm 2007;67:112-119.
8. Laine E, Tuominen V, Ilvessalo P, Kahela P.Formation of dihydrate from carbamazepine anhydrate in aqueous conditions.Int J Pharm 1984;20:307-314.
9. Young WW, Suryanarayanan R.Kinetics of transition of anhydrous carbamazepine to carbamazepine dihydrate in aqueous suspensions.J Pharm Sci 1991;80:496-500.
10. Luhtala S.Effect of sodium lauryl sulphate and polysorbate 80 on crystal growth and aqueous solubility of carbamazepine.Acta Pharm Nord 1992;4:85-90.
11. Trask AV, Motherwell WDS, Jones W.Physical stability enhancement of theophylline via cocrystallization.Int J Pharm 2006;320:114-123.
12. Karki S, Frišcić T, Fábián L, Laity PR, Day GM, Jones W.Improving mechanical properties of crystalline solids by cocrystal formation: new compressible forms of paracetamol.Adv Mat 2009;21:3905-3909.
13. McNamara DP, Childs SL, Giordano J, Iarriccio A, Cassidy J, Shet MS, Mannion R, O'Donnell E, Park A.Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.Pharma Res 2006;23:1888-1897.
14. Variankaval N, Wenslow R, Murry J, Hartman R, Helmy R, Kwong E, Clas SD, Dalton.C, Santos I.Preparation and solidstate characterization of nonstoichiometric co-crystals of a phosphodiesterase-IV inhibitor and L-tartaric acid.Cryst Growth Des 2006;6:690-700.
15. Good DJ, Rodríguez-Hornedo N.Solubility advantage of pharmaceuticalcocrystals.Crystal Growth Des 2009;9:2252-2264.
16. Rodríguez-Hornedo N, Nehm SJ, Seefeldt KF, Pag án-Torres Y, Falkiewicz CJ.Reaction crystallization of pharmaceutical molecular complexes.Mol Pharm 2006;3:362-367.
17. http://www.accessdata.fda.gov/scripts/cder/iig/getiigWEB.cfm
18. Padrela L, Rodrigues MA, Velaga SP, Matos HA, de Azevedo EG.Formation of indomethacin-saccharin cocrystals using supercritical fluid technology.Eur J Pharm Sci 2009;38:9-17.
19. Shiraki K, Takata N, Takano R, Hayashi Y, Terada K.Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds.Pharm Res 2008;25:2581-2592.
20. Takata N, Takano R, Uekusa H, Hayashi Y, Terada K.A spironolactone- saccharin 1:1 cocrystal hemihydrate.Cryst Growth Des 2010;10: 2116-2122.
21. Velaga SP, Basavoju S Boström D.Norfloxacin saccharinatesaccharin dihydrate cocrystal - A new pharmaceutical cocrystal with an organic counter ion.J Mol Struct 2008;889:150-153.
22. Aitipamula S, Chow PS, Tan RBH.Dimorphs of a 1:1 cocrystal of ethenzamide and saccharin: solid-state grinding methods result in metastable polymorph.Cryst Eng Comm 2009;11:889-895.
23. Jayasankar A, Good DJ, Rodríguez-Hornedo N.Mechanisms by which moisture generates cocrystals.Mol Pharm 2007;4:360-372.
24. Zakeri-Milani P, Barzegar-Jalali M, Azimi M, Valizadeh H.Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability.Eur J Pharm Biopharm 2009;73:102-106.
25. Bethune SJ, Huang N, Jayasankar A, Rodriguez-Hornedo N.Understanding and predicting the effect of cocrystal components and pH on cocrystal solubility.Cryst Growth Des 2009;9:3976-3988.
26. International conference of harmonization-validation of analytical procedures Q2(R1), 2005.
27. Fell JT, Newton JM.The tensile strength of lactose tablets.J Pharm Pharmacol 1968;20:657-758.
28. Heckel RW.An analysis of powder compaction phenomena.Trans AIME 1996;221:1001-1008.
29. Paronen P, Iilla J.1996.Porosity-pressure functions.In: Alderborn G, Nyström C, eds, Pharmaceutical Powder Compaction Technology.New York: Marcel Dekker Inc, 1996:55-75.
30. Murphy D, Rodríguez-Cintrón F, Langevin B, Kelly RC, Rodríguez-Hornedo N.Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder.Int J Pharm 2002;246:121-134.
31. Banerjee R, Bhatt PM, Ravindra NV, Desiraju GR.Saccharins salts of active pharmaceutical ingredients, their crystal structures, and increased water solubilities.Cryst Growth Des 2005;5:2299-2309.
32. Nair R, Nyamweya N, Gonen S, Martinez-Miranda LJ, Hoag SW.Influence of various drugs on the glass transition temperature of poly(vinylpyrrolidone): a thermodynamic and spectroscopic investigation.Int J Pharm 2001;225:83-96.
33. Hase Y.1978.The infrared and Raman spectra of phthalimide, N-D-phthalimide and potassium phthalimide.J Mol Struct 1978;48:33-42.
34. Jovanovski G, Tanceva S, Soptrajanov B.The SO2 stretching vibrations in some metal saccharinates: spectra-structure correlations.Spectrosc Lett 1995;28:1095-1109.
35. Jayasankar A, Somwangthanaroj A, Shao ZJ, Rodríguez-Hornedo N.Cocrystal formation during cogrinding and storage is mediated by amorphous phase.Pharm Res 2006;23:2381-2392.
36. Fleischman SG, Kuduva SS, McMahon JA, Moulton B, Walsh RDB, Rodríguez-Hornedo N, Zaworotko MJ.Crystal engineering of the composition of pharmaceutical phases: multiple component crystalline solids involving carbamazepine.Cryst Growth Des 2003;3:909-919
37. Porter WW, Elie SC, Matzger AJ.Polymorphism in carbamazepine cocrystals.Cryst Growth Des 2008;8:14-16.
38. Saravanan M, Nataraj KS, Ganesh KS.The effect of tablet formulation and hardness on in vitro release of cephalexin from Eudragit L100 based extended release tablets.Bio Pharm Bull 2002;25:541-545.
39. Ahmed A, Ali SA, Hassan F, Ali SS, Haque N.Dissolution rate studies on acetaminophen tablets.Pak J Pharm Sci 1999;13:39-43
40. Carstensen JT, Hou XP.The Athy-Heckel equation applied to granular agglomerates of basic tricalcium phosphate [3Ca3PO4)2.Ca(OH)2].Powder Technol 1985;42:153-157.
41. Sonnergaard JM.A critical evaluation of the Heckel equation.Int J Pharm 1999;193:63-71.
42. Baie SB, Newton JM, Podczeck F.The characterization of the mechanical properties of pharmaceutical materials.Eur J Pharm Biopharm 1996;43:138-141.
43. Kobayashi Y, Ito S, Itai S, Yamamoto K.Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate.Int J Pharm 2000;193:137-146.